NF-κB-IN-8 

NF-κB-IN-8 competitively antagonizes LPS binding to MD-2. NF-κB-IN-8 reduces the expression of inflammatory factors by binding to MD-2. NF-κB-IN-8 also inhibits ALP activity. NF-κB-IN-8 can be used for the research of inflammation such as acute lung injury (ALI)^[1].

NF-κB-IN-8 (Compound L26) (10 μM) inhibits ALP activity by 64.30%^[1].
NF-κB-IN-8 (1-10 μM, 24 h) inhibits expression of IL-6 and TNF-α in RAW 264.7 cells^[1].
NF-κB-IN-8 (0-50 μM) inhibits the binding of LPS to MD-2, determined by ELISA Asssay^[1].
NF-κB-IN-8 (50 μM, overnight) inhibits the formation of LPS/MD-2/TLR4 polymers in RAW264.7 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

NF-κB-IN-8 (Compound L26) (5 mg/kg, intra-gastrically administration) attenuates LPS-induced ALI in mice^[1].
NF-κB-IN-8 (1000 and 1500 mg/kg, intra-gastrically administration) is low in toxic and safe in mice^[1].
NF-κB-IN-8 (10 mg/kg, rats) shows T_1/2: 4.2 h, C_max: 163.288 μg/L^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

399.44

C₂₄H₂₁N₃O₃

2924565-59-1

COC1=CC=CC(COC2=CC=C(C=C2)/C=C/C(NC3=NC4=C(N3)C=CC=C4)=O)=C1

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Li X, et al. Novel O-benzylcinnamic acid derivative L26 treats acute lung injury in mice by MD-2. Eur J Med Chem. 2023 Apr 5;252:115289.  [Content Brief]